glun2d antagonists Search Results


glun2d-selective nmda receptor antagonist ubp145 (cat. no. hb4717)  (Hello Bio Inc)
90
Hello Bio Inc glun2d-selective nmda receptor antagonist ubp145 (cat. no. hb4717)
GluN2C/D-containing NMDA receptors were not involved in synaptic depression after synaptic potentiation. (a) The summarized fEPSP slope plot about the effect of PPDA (GluN2C/D-selective NMDA receptors antagonist, 10 µM) on synaptic depression after potentiation (n = 9 slices/8 mice). (b) Statistical results showed that significant difference was observed between TBS and LFS by comparisons of the last 10 min fEPSP slopes in presence of PPDA (TBS: 130.48 ± 2.80% of the baseline; LFS: 102.98 ± 6.17%). ** p <0.01, paired t -test, compared with TBS. (c) The averaged fEPSP slope plot about the effect of <t>UBP145</t> <t>(GluN2D-selective</t> NMDA receptors antagonist, 3 µM) on synaptic depression after potentiation (n = 14 slices/11 mice). (d) Statistical results showed that the averaged fEPSP slope after TBS was higher than that of LFS (TBS: 123.94 ± 1.77%; LFS: 114.43 ± 3.56% of the baseline; * p <0.05, paired t -test, compared with TBS). Error bars indicated SEM.
Glun2d Selective Nmda Receptor Antagonist Ubp145 (Cat. No. Hb4717), supplied by Hello Bio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glun2d-selective nmda receptor antagonist ubp145 (cat. no. hb4717)/product/Hello Bio Inc
Average 90 stars, based on 1 article reviews
glun2d-selective nmda receptor antagonist ubp145 (cat. no. hb4717) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
glun2d antagonists  (Janssen)
90
Janssen glun2d antagonists
GluN2C/D-containing NMDA receptors were not involved in synaptic depression after synaptic potentiation. (a) The summarized fEPSP slope plot about the effect of PPDA (GluN2C/D-selective NMDA receptors antagonist, 10 µM) on synaptic depression after potentiation (n = 9 slices/8 mice). (b) Statistical results showed that significant difference was observed between TBS and LFS by comparisons of the last 10 min fEPSP slopes in presence of PPDA (TBS: 130.48 ± 2.80% of the baseline; LFS: 102.98 ± 6.17%). ** p <0.01, paired t -test, compared with TBS. (c) The averaged fEPSP slope plot about the effect of <t>UBP145</t> <t>(GluN2D-selective</t> NMDA receptors antagonist, 3 µM) on synaptic depression after potentiation (n = 14 slices/11 mice). (d) Statistical results showed that the averaged fEPSP slope after TBS was higher than that of LFS (TBS: 123.94 ± 1.77%; LFS: 114.43 ± 3.56% of the baseline; * p <0.05, paired t -test, compared with TBS). Error bars indicated SEM.
Glun2d Antagonists, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glun2d antagonists/product/Janssen
Average 90 stars, based on 1 article reviews
glun2d antagonists - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


GluN2C/D-containing NMDA receptors were not involved in synaptic depression after synaptic potentiation. (a) The summarized fEPSP slope plot about the effect of PPDA (GluN2C/D-selective NMDA receptors antagonist, 10 µM) on synaptic depression after potentiation (n = 9 slices/8 mice). (b) Statistical results showed that significant difference was observed between TBS and LFS by comparisons of the last 10 min fEPSP slopes in presence of PPDA (TBS: 130.48 ± 2.80% of the baseline; LFS: 102.98 ± 6.17%). ** p <0.01, paired t -test, compared with TBS. (c) The averaged fEPSP slope plot about the effect of UBP145 (GluN2D-selective NMDA receptors antagonist, 3 µM) on synaptic depression after potentiation (n = 14 slices/11 mice). (d) Statistical results showed that the averaged fEPSP slope after TBS was higher than that of LFS (TBS: 123.94 ± 1.77%; LFS: 114.43 ± 3.56% of the baseline; * p <0.05, paired t -test, compared with TBS). Error bars indicated SEM.

Journal: Molecular Pain

Article Title: NMDA Receptor-Dependent Synaptic Depression in Potentiated Synapses of the Anterior Cingulate Cortex of adult Mice

doi: 10.1177/17448069211018045

Figure Lengend Snippet: GluN2C/D-containing NMDA receptors were not involved in synaptic depression after synaptic potentiation. (a) The summarized fEPSP slope plot about the effect of PPDA (GluN2C/D-selective NMDA receptors antagonist, 10 µM) on synaptic depression after potentiation (n = 9 slices/8 mice). (b) Statistical results showed that significant difference was observed between TBS and LFS by comparisons of the last 10 min fEPSP slopes in presence of PPDA (TBS: 130.48 ± 2.80% of the baseline; LFS: 102.98 ± 6.17%). ** p <0.01, paired t -test, compared with TBS. (c) The averaged fEPSP slope plot about the effect of UBP145 (GluN2D-selective NMDA receptors antagonist, 3 µM) on synaptic depression after potentiation (n = 14 slices/11 mice). (d) Statistical results showed that the averaged fEPSP slope after TBS was higher than that of LFS (TBS: 123.94 ± 1.77%; LFS: 114.43 ± 3.56% of the baseline; * p <0.05, paired t -test, compared with TBS). Error bars indicated SEM.

Article Snippet: Selective competitive NMDA receptor antagonist AP-5 (Cat. No. HB0225) and GluN2D-selective NMDA receptor antagonist UBP145 (Cat. No. HB4717) were purchased from HelloBio (Princeton, NJ, USA).

Techniques: